MariTide vs. Zepbound

MariTide (AMG 133) und Tirzepatide (Zepbound) verfolgen radikal unterschiedliche Ansätze bezüglich des GIP-Rezeptors. Während Zepbound ihn aktiviert, blockiert MariTide ihn. Der größte Vorteil von MariTide könnte die monatliche Anwendung sein, was die Therapietreue massiv erleichtert.

Zepbound ist jedoch bereits etabliert und verfügt über umfangreiche Langzeitdaten zur Sicherheit und Wirksamkeit.

Choosing between Maritide and Zepbound depends on multiple individual factors including your specific health goals, tolerance profile, insurance coverage, and prescriber recommendation. While clinical trial data provides population-level efficacy and safety comparisons, your personal response may differ based on genetics, baseline health, concurrent conditions, and lifestyle factors. Use this comparison as a starting framework and discuss the specifics with your healthcare provider.

Head-to-head clinical trial data between Maritide and Zepbound is the gold standard for comparison, but such direct comparisons are not always available for every pair of compounds. Where head-to-head data is lacking, cross-trial comparisons provide useful but imperfect approximations — differences in patient populations, trial design, and endpoint definitions mean that numbers from separate trials are not directly interchangeable. Keep this context in mind when evaluating the comparison data presented here.

Tracking your personal response data in Shotlee is particularly valuable when switching between medications or considering a change. By documenting your outcomes on your current protocol — including efficacy metrics, side effect profile, adherence rate, and quality of life measures — you create an objective baseline for comparison if you transition to the alternative compound. This data transforms a subjective switching decision into an evidence-based protocol optimization.